Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fluorine (18F) psma-1007 (ABX advanced biochemical compounds)
- Development stage
- Unknown
- Lead developer
- ABX
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
F18 PSMA-1007 (fluorine (18F) psma-1007) is a fluorine-18 labeled, small-molecule radiopharmaceutical that targets prostate-specific membrane antigen (PSMA). It was originated by the German Cancer Research Center (DKFZ) and developed by Advanced Biochemical Compounds (ABX) and other partners. It is used as a diagnostic imaging agent for positron emission tomography (PET) in patients with prostate cancer, specifically for primary staging of high-risk prostate cancer and restaging in biochemical recurrence. Unlike some other PSMA-targeting tracers (such as Ga-68 PSMA-11), F18 PSMA-1007 is primarily excreted via the hepatobiliary system rather than the urinary tract, which reduces background activity in the bladder and improves the visualization of pelvic lesions.
- Brand names
- RadeluminSWAN-PSMA-1007SWAN-PSMA1007SWAN-PSMA 1007
- Other names
- [18F]-PSMA-1007[18F]PSMA-100718F-PSMA-1007F-18-PSMA-1007F18-PSMA-1007F 18-PSMA-1007F18 PSMA-1007F-18 PSMA-1007F 18 PSMA-1007fluorine-18 psma-1007fluorine18 psma-1007fluorine 18 psma-1007
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on fluorine (18F) psma-1007 (ABX advanced biochemical compounds).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fluorine (18F) psma-1007 (ABX advanced biochemical compounds).